These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress.
    Journal: Prescrire Int; 2013 Oct; 22(142):233-5. PubMed ID: 24298581.
    Abstract:
    First-line treatment of HIV-1 infection currently consists of a combination of at least three antiretroviral drugs belonging to two different classes: for example, efavirenz + tenofovir + emtricitabine or lopinavir + ritonavir + tenofovir + emtricitabine. Following marketing authorisation in the United States, a marketing application has been submitted in the European Union for the fixed-dose combination of cobicistat (CYP 3A inhibitor), elvitegravir (HIV integrase inhibitor), emtricitabine and tenofovir (HIV reverse transcriptase inhibitors). Clinical evaluation is based on two "non-in feriority" trials, one versus efavirenz + emtricitabine + tenofovir, and the other versus atazanavir+ ritonavir + emtricitabine + tenofovir. Overall, about 85% of patients achieved undetectable viral load 48 weeks after treatment initiation. The cobicistat + elvitegravir + emtricitabine + tenofovircombination had the usual adverse effects of antiretroviral combinations (diarrhoea, nausea, upper respiratory tract infections, neuropsychological disorders, etc.), plus musculoskeletal disorders and renal toxicity. Cobicistat carries a high risk of interactions. The cobicistat + elvitegravir + emtricitabine + tenofovir combination is taken as a single daily tablet. In practice, given the lack of therapeutic progress, it is best to stick with better-documented antiretroviral combinations.
    [Abstract] [Full Text] [Related] [New Search]